CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform.
| Website: | www.cytomx.com |
| Email: | bgoeltz@cytomx.com |
| Main Phone: | +1 650 515-3185 |
| Address: | 151 Oyster Point Boulevard |
| Address 2: | Suite 400 |
| State: | CA |
| City / Town: | South San Francisco |
| Country: | USA |
| Postal Code: | 94080 |
| Exchange: | NGS |
| CEO: | Sean A. McCarthy |
| Employees: | 92 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 18.49 | Change $ -0.02 | Change % -0.11 | Tick N/A |
| Bid 14.15 | Bid Size 100.00 | Ask 18.98 | Ask Size 400.00 |
| Open 18.51 | High 18.98 | Low 18.46 | Prev Close 18.51 |
| Last Trade | Volume 234,764 | 52 Wk Hi 35.00 | 52 Wk Low 17.02 |
| Market Cap 831.4 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 44,963,692.00 | EPS (TTM) -1.00 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 11 | 84 |
| Number of Buys | 6 | 34 |
| Number of Sells | 5 | 50 |
| Net Activity | -3511 | -1977686 |
| Last 10 Buys | Shares |
|---|---|
| Flynn E James | 1,000 |
| Flynn E James | 1,000 |
| Cynthia Ladd | 1,000 |
| W. Michael Kavanaugh | 1,000 |
| Frederick W. Gluck | 1,000 |
| Frederick W. Gluck | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Debanjan Ray | 1,000 |
| Debanjan Ray | 1,000 |
| Sean A. McCarthy | 1,000 |
| Debanjan Ray | 1,000 |
| Frederick W. Gluck | 1,000 |
| Debanjan Ray | 1,000 |
| Debanjan Ray | 1,000 |
| Rachel Humphrey | 1,000 |
| Frederick W. Gluck | 1,000 |
| Debanjan Ray | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 40 | 40 | 40 | 40 |
| Low Target Price Estimate | 37 | 37 | 37 | 37 |
| Mean Target Price Estimate | 39 | 39.2 | 39.2 | 39 |
| Standard Deviation | 1.26 | 1.3 | 1.3 | 1.26 |
| Date of Most Recent Estimate | 06/05/18 | 05/22/18 | 05/22/18 | 06/05/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-06-04 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.25 | 1.29 | 1.29 | 1.29 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
